These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation. Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052 [TBL] [Abstract][Full Text] [Related]
4. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. Asante-Korang A; Boyle GJ; Webber SA; Miller SA; Fricker FJ J Heart Lung Transplant; 1996 Apr; 15(4):415-22. PubMed ID: 8732602 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M; Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208 [TBL] [Abstract][Full Text] [Related]
6. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242 [TBL] [Abstract][Full Text] [Related]
7. Renal function in pediatric liver transplant patients. McDiarmid SV Kidney Int Suppl; 1996 Jan; 53():S77-84. PubMed ID: 8770996 [TBL] [Abstract][Full Text] [Related]
8. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. Ogita K; Takada N; Taguchi T; Suita S; Soejima Y; Suehiro T; Shimada M; Maehara Y Asian J Surg; 2003 Oct; 26(4):218-20. PubMed ID: 14530108 [TBL] [Abstract][Full Text] [Related]
9. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259 [TBL] [Abstract][Full Text] [Related]
10. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635 [TBL] [Abstract][Full Text] [Related]
11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related]
12. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus]. Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease]. Yu LX; Shan HT; Fu SJ; Du CF; Ma JJ; Xu J; Deng WF; Wang YB Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1146-8. PubMed ID: 14625173 [TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762 [TBL] [Abstract][Full Text] [Related]
15. The role of testosterone in cyclosporine-induced osteopenia. Bowman AR; Sass DA; Dissanayake IR; Ma YF; Liang H; Yuan Z; Jee WS; Epstein S J Bone Miner Res; 1997 Apr; 12(4):607-15. PubMed ID: 9101372 [TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P Transplantation; 1994 Jul; 58(2):170-8. PubMed ID: 7518975 [TBL] [Abstract][Full Text] [Related]
17. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P Clin Transplant; 1995 Jun; 9(3 Pt 1):176-84. PubMed ID: 7549057 [TBL] [Abstract][Full Text] [Related]
18. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069 [TBL] [Abstract][Full Text] [Related]
19. [Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients]. Liu XY; Yu LX; Fu SJ; Xu J; Du CF; Deng WF; Wang YB; Ye GR; Zhang YX Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1090-2. PubMed ID: 17666359 [TBL] [Abstract][Full Text] [Related]
20. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]